TransCode Therapeutics (RNAZ) Institutional Ownership $10.39 -0.26 (-2.44%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$10.04 -0.35 (-3.32%) As of 08/8/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for TransCode Therapeutics (NASDAQ:RNAZ)Number ofInstitutional Buyers(last 12 months)3TotalInstitutional Inflows(last 12 months)$563.55MNumber ofInstitutional Sellers(last 12 months)0 Get RNAZ Insider Trade Alerts Want to know when executives and insiders are buying or selling TransCode Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data RNAZ Institutional Buying and Selling by Quarter TransCode Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/28/2025Anson Funds Management LP1,462,112$724K0.1%N/A175.524% 5/14/2025Anson Funds Management LP1,462,112$724K0.1%N/A6.264% 5/9/2025Warberg Asset Management LLC50,000$25K0.0%N/A0.214% 11/1/2024 Sheets Smith Wealth Management50,138$29K0.0%+149.0%0.290% 5/20/2024Virtu Financial LLC55,329$37K0.0%N/A0.836% 11/15/2023Sabby Management LLC250,309$126K0.1%+32.8%12.330% 4/21/2022 K.J. Harrison & Partners Inc19,987$58K0.0%+24.9%0.155% 2/4/2022 Redmond Asset Management LLC88,010$224K0.1%N/A0.682% 1/26/2022 K.J. Harrison & Partners Inc16,000$41K0.0%N/A0.124% 11/16/2021ACT Capital L.L.C.50,000$150K0.1%N/A0.387% 11/16/2021National Asset Management Inc.25,000$75K0.0%N/A0.194% 11/16/2021Two Sigma Securities LLC33,314$100K0.0%N/A0.258% 11/12/2021 AIGH Capital Management LLC1,270,500$3.80M0.8%N/A9.845% (Data available from 1/1/2016 forward) RNAZ Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of RNAZ shares? During the previous two years, the following institutional investors and hedge funds held shares of TransCode Therapeutics shares: Anson Funds Management LP ($724K), Sabby Management LLC ($126K), Virtu Financial LLC ($37K), and Sheets Smith Wealth Management ($29K), Warberg Asset Management LLC ($25K).Learn more on TransCode Therapeutics' institutional investors. Which institutional investors have been buying TransCode Therapeutics' stock? The following institutional investors have purchased TransCode Therapeutics' stock in the last 24 months: Anson Funds Management LP ($2.92M), Sabby Management LLC ($61.87K), Virtu Financial LLC ($55.33K), Warberg Asset Management LLC ($50K), and Sheets Smith Wealth Management ($30K). How much institutional buying is happening at TransCode Therapeutics? Institutional investors have bought a total of 3,004,224 shares in the last 24 months. This purchase volume represents approximately $563.55M in transactions. Related Companies LAVA Therapeutics Institutional Ownership Sol-Gel Technologies Institutional Ownership Ovid Therapeutics Institutional Ownership Shattuck Labs Institutional Ownership Medicus Pharma Institutional Ownership Enlivex Therapeutics Institutional Ownership Karyopharm Therapeutics Institutional Ownership Xilio Therapeutics Institutional Ownership Rani Therapeutics Institutional Ownership Mersana Therapeutics Institutional Ownership This page (NASDAQ:RNAZ) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access Sale